Navigation Links
Antithrombotic/Anticoagulant Drugs: World Market 2012-2022
Date:5/3/2012

NEW YORK, May 3, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Antithrombotic/Anticoagulant Drugs: World Market 2012-2022

http://www.reportlinker.com/p0325493/Antithrombotic/Anticoagulant-Drugs-World-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

 

Report Details

 

Where are antithrombotic and anticoagulant treatments heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.

 

This study assesses drugs to treat abnormal blood clotting in human beings. Discover sales predictions at world market, therapeutic class, product and national levels to 2022.

 

How will products - Plavix, Lovenox, Pletal, Fragmin, Asasantin, Arixtra, Aspirin Cardio, Effient, Pradaxa, Brilinta and others - perform? Our report gives you business research and analysis with many sales predictions. See the future of the industry and market.

 

Also, receive forecasting of submarkets, finding potential sales trends from 2012:

• Platelet aggregation inhibitors

• Heparins

• Fibrinolytics

• Vitamin K antagonists

• Direct thrombin inhibitors

• Direct factor Xa inhibitors.

 

Our report discusses activities of Eli Lilly, Boehringer Ingelheim, AstraZeneca, J&J, Bayer, Sanofi, Merck, Eisai, Daiichi Sankyo and other pharmaceutical companies.

 

What does the future hold? With its R&D pipelines, the pharma industry has potential for improved treatments and increased revenues from blood-thinning agents. Many commercial opportunities remain.

 

Worldwide, numbers of heart attacks and strokes will rise this decade. Blood thinners will play important roles in medicine, helping to prevent and treat cardiovascular disorders.

 

Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You will find answers in our work.

 

Revenue forecasts, market shares, developmental trends, discussions and interviews

 

In the report you find revenue forecasting, growth rates, market shares, qualitative analyses (including SWOT and STEP), opinions and R&D news. You receive 82 tables and charts and four research interviews.

 

Advantages of Antithrombotic/Anticoagulant Drugs: World Market 2012-2022 for your work

 

In particular, this study gives you the following knowledge and benefits:

• Find revenue predictions to 2022 for the overall world market and submarkets

• Discover revenue forecasts to 2022 for 14 drugs, assessing commercial potential

• See revenue forecasts to 2022 for leading national markets - US, Japan, Germany, France, UK,Spain, Italy, China and India

• Assess leading companies, discovering activities and outlooks

• Review R&D, seeing pipeline trends

• Investigate competition and opportunities influencing sales results

• Find out what will stimulate and restrain the industry and market

• View opinions from our survey of authorities on the sector.

 

There, you receive a distinctive mix of quantitative and qualitative work with independent predictions. We analyse developments and prospects, helping you to stay ahead.

 

Gain business research, data and analysis for treatment of blood clotting disorders

 

Our study is for everybody needing industry and market analyses for blood-thinning drugs. Find data, trends and answers. Avoid missing out - please order our report now.

 

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

 

 

 

Table of Contents

 

1. Executive Summary

1.1 Antithrombotic/Anticoagulant Drug: World Market Overview

1.2 Aims, Scope and Format of the Report

1.3 Research and Analysis Methods

 

2. Blood Clotting: Mechanism, Disorders and Treatments

2.1 Thrombosis

2.1.1 Venous Thrombosis

2.1.2 Arterial Thrombosis

2.2 Complications of Thrombosis

2.2.1 Pulmonary Embolism

2.2.2 Stroke

2.2.3 Myocardial Infarction

2.2.4 Acute Coronary Syndrome

2.3 Antithrombotic Treatments

2.3.1 Platelet Aggregation Inhibitors

2.3.1.1 Glycoprotein Inhibitors

2.3.1.2 Aspirin

2.3.1.3 Thienopyridines

2.3.2 Heparins

2.3.3 Fibrinolytics

2.3.3.1 Streptokinase and Urokinase

2.3.3.2 Tissue Plasminogen Activator (tPA)

2.3.3.3 Other Thrombolytic Agents

2.3.4 Vitamin K Antagonists

2.3.5 Direct Thrombin Inhibitors

2.3.6 Direct Factor Xa Inhibitors

 

3. Antithrombotic Drugs: World Market 2012-2022

3.1 The Antithrombotic/Anticoagulant Drug Market in 2010

3.2 The Antithrombotic/Anticoagulant Drug Market Forecast 2012-2022

3.3 The Leading Antithrombotic/Anticoagulant Therapeutic Classes

3.3.1 The Leading Therapeutic Classes in 2010

3.3.2 Leading Therapeutic Class Forecast 2012-2022

3.4 Platelet Aggregation Inhibitors

3.4.1 Platelet Aggregation Inhibitors Dominated the Market in 2010

3.4.2 Platelet Aggregation Inhibitors: Market Forecast 2012-2022

3.5 Heparins

3.5.1 The Heparins Market in 2010

3.5.2 Heparins: Market Forecast 2012-2022

3.6 Fibrinolytics

3.6.1 The Fibrinolytics Market in 2010

3.6.2 Fibrinolytics: Market Forecast 2012-2022

3.7 Vitamin K Antagonists

3.7.1 Vitamin K Antagonists Market in 2010

3.7.2 Vitamin K Antagonists Market Forecast 2012-2022

3.8 Direct Thrombin Inhibitors

3.8.1 Direct Thrombin Inhibitors Market in 2010

3.8.2 Direct Thrombin Inhibitors: Market Forecast 2012-2022

3.9 Direct Factor Xa Inhibitors

3.9.1 Direct Factor Xa Inhibitors Market in 2010

3.9.2 Direct Factor Xa Inhibitors: Market Forecast 2012-2022

3.10 Chapter Summary

 

4. Leading National Markets for Antithrombotic/Anticoagulant Drugs, 2012-2022

4.1 Leading National Markets in 2010

4.2 Leading National Markets: Forecasts to 2022

4.3 The US Antithrombotic/Anticoagulant Drug Market, 2012-2022

4.4 The Japanese Antithrombotic/Anticoagulant Drug Market, 2012-2022

4.5 Leading European Antithrombotic/Anticoagulant Drug Markets, 2012-2022

4.6 The Chinese Antithrombotic/Anticoagulant Drug Market, 2012-2022

4.7 The Indian Antithrombotic/Anticoagulant Drug Market, 2012-2022

 

5. Leading Antithrombotic/Anticoagulant Drugs, 2012-2022

5.1 The Leading Drugs of 2010

5.2 Plavix - Commercial Prospects

5.2.1 Plavix: The Leading Anticoagulant of 2010

5.2.2 Plavix Sales Forecast, 2012-2022

5.2.3 Generic Competition

5.2.4 Branded Competition

5.3 Lovenox

5.3.1 Lovenox Sales Forecast, 2012-2022

5.3.2 Competition for Lovenox

5.4 Pletal

5.4.1 Pletal Sales, 2010

5.4.2 Pletal Sales Forecast, 2012-2022

5.5 Fragmin

5.5.1 Fragmin Sales, 2010

5.5.2 Fragmin Sales Forecast, 2012-2022

5.6 Asasantin

5.6.1 Asasantin Sales, 2010

5.6.2 Asasantin Sales Forecast, 2012-2022

5.7 Arixtra

5.7.1 Arixtra Sales, 2010

5.7.2 Arixtra Sales Forecast, 2012-2022

5.8 Aspirin Cardio

5.8.1 Aspirin Cardio Sales, 2010

5.8.2 Aspirin Cardio Sales Forecast, 2012-2022

5.9 Opalmon

5.9.1 Opalmon Sales, 2010

5.9.2 Opalmon Sales Forecast, 2012-2022

5.10 Angiomax

5.10.1 Angiomax Sales, 2010

5.10.2 Angiomax Sales Forecast, 2012-2022

5.11 Activase

5.11.1 Activase Sales, 2010

5.11.2 Activase Sales Forecast, 2012-2022

5.12 Newly Launched Drugs, 2009-2011

5.12.1 Eli Lilly's Effient

5.12.1.1 Effient Sales Forecast, 2012-2022

5.12.1.2 Competition for Effient

5.12.2 Boehringer Ingelheim's Pradaxa

5.12.2.1 Pradaxa Sales Forecast, 2012-2022

5.12.2.2 Competition for Pradaxa

5.12.3 AstraZeneca's Brilinta

5.12.3.1 Brilinta Sales Forecast, 2012-2022

5.12.3.2 Competition for Brilinta

5.12.4 Johnson & Johnson/Bayer's Xarelto

5.12.4.1 Xarelto Sales Forecast, 2012-2022

5.12.4.2 Competition for Xarelto

5.13 Chapter Summary

 

6. Antithrombotic/Anticoagulant Drug R&D Pipeline

6.1 Platelet Aggregation Inhibitors R&D Pipeline, 2011

6.1.1 Portola/Novartis's Elinogrel

6.2 Heparins R&D Pipeline, 2011

6.2.1 Sanofi's Semuloparin

6.3 Fibrinolytics R&D Pipeline, 2011

6.3.1 Lundbeck/Berlex/Bayer's Desmoteplase

6.4 Direct Thrombin Inhibitors R&D Pipeline, 2011

6.4.1 Merck's Vorapaxar

6.4.2 Eisai's Atopaxar

6.5 Direct Factor Xa Inhibitors R&D Pipeline, 2011

6.5.1 BMS/Pfizer's Apixaban

6.5.2 Portola's Betrixaban

6.5.3 Daiichi Sankyo's Edoxaban

6.6 R&D Pipeline for Other Antithrombotic Drugs, 2011

6.6.1 Endotis/Merck's EP217609

 

7. SWOT and STEP Analyses

7.1 Principal Market Drivers

7.1.1 Rising Disease Prevalence

7.1.2 Risk Factors: Management Rather Than Cure

7.1.3 Opportunities for Continuous Growth

7.1.3.1 Standing Out from Competitors

7.1.3.2 Cost-Effective Replacement of Warfarin

7.1.3.3 Antidotes in Demand

7.1.3.4 Further Development of Existing Drugs

7.1.3.5 Exploring New Markets

7.1.4 Advances in Technology Will Bring Benefits to the Market

7.2 Principal Market Restraints

7.2.1 Highly Competitive Market

7.2.1.1 Generic Competition

7.2.1.2 Branded Competition

7.2.2 Cost-Reduction Pressure

7.2.3 Stringent Regulations

 

8. Research Interviews

8.1 Interview with Dr Charles E. Mahan (Director of Outcomes Research, New Mexico Heart Institute,Albuquerque, New Mexico)

8.1.1 Unmet Needs

8.1.2 Major Areas of Focus

8.1.3 New Drug Potential

8.1.4 Key Market Drivers

8.1.5 Opportunities for Revenue Growth

8.2 Interview with Dr Maurice Petitou (Head of Preclinical Research and Development, Endotis Pharma)

8.2.1 EP217609: The First Neutralizable Anticoagulant

8.2.2 Drug Targets Worth Exploring

8.2.3 New Drug Potential

8.2.4 Unmet Needs

8.3 Interview with Dr Jonathan L. Halperin (Professor of Medicine, Director of Clinical Cardiology Services, Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai Medical Center, New York)

8.3.1 Unmet Needs

8.3.2 New Findings

8.3.3 Warfarin Replacement

8.3.4 Areas Demanding Attention

8.3.5 Key Market Restraints

8.4 Interview with Dr Jeffrey I. Weitz (Professor of Medicine & Biochemistry, McMaster University, and Executive Director, Thrombosis & Atherosclerosis Research Institute, Ontario)

8.4.1 Unmet Needs

8.4.2 New Oral Anticoagulants

8.4.3 Future Areas of Focus

8.4.4 New Drug Potential

8.4.5 Market Drivers and Restraints

 

9. Conclusions

9.1 World Market Overview to 2022

9.2 Leading Drug Classes

9.3 Leading Products

9.4 Leading National Markets

9.5 The Future of the Antithrombotic/Anticoagulant Drug Market

9.5.1 Challenges

9.5.2 Opportunities

 

List of Tables

Table 3.1 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2016

Table 3.2 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2017-2022

Table 3.3 Leading Antithrombotic/Anticoagulant Therapeutic Classes: Sales ($bn) and Market Shares (%), 2010

Table 3.4 Antithrombotic/Anticoagulant Therapeutic Class Forecasts ($bn), 2010-2016

Table 3.5 Antithrombotic/Anticoagulant Therapeutic Class Forecasts ($bn), 2017-2022

Table 3.6 Platelet Aggregation Inhibitors: Market Forecast ($bn), 2010-2022

Table 3.7 Heparins: Market Forecast ($bn), 2010-2022

Table 3.8 Fibrinolytics: Market Forecast ($bn), 2010-2022

Table 3.9 Vitamin K Antagonists: Market Forecast ($bn), 2010-2022

Table 3.10 Direct Thrombin Inhibitors: Market Forecast ($bn), 2010-2022

Table 3.11 Direct Factor Xa Inhibitors: Market Forecast ($bn), 2010-2022

Table 4.1 Antithrombotic/Anticoagulant Drugs: Leading National Markets, 2010

Table 4.2 Leading National Markets: Forecasts ($bn), 2010-2022

Table 4.3 Antithrombotic/Anticoagulant Drug Market Shares (%) by Country, 2012 & 2022

Table 4.4 US Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022

Table 4.5 Japanese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022

Table 4.6 Leading European Antithrombotic/Anticoagulant Drug Market Forecasts ($bn), 2010-2022

Table 4.7 Chinese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022

Table 4.8 Indian Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022

Table 5.1 Leading Antithrombotic/Anticoagulant Drugs: Sales ($m) and Market Shares (%), 2010

Table 5.2 Leading Antithrombotic/Anticoagulant Drugs: Forecasts ($m), 2010-2022

Table 5.3 Plavix Sales Forecast ($m), 2010-2022

Table 5.4 Lovenox Sales Forecast ($m), 2010-2022

Table 5.5 Pletal Sales Forecast ($m), 2010-2022

Table 5.6 Fragmin Sales Forecast ($m), 2010-2022

Table 5.7 Asasantin Sales Forecast ($m), 2010-2022

Table 5.8 Arixtra Sales Forecast ($m), 2010-2022

Table 5.9 Aspirin Cardio Sales Forecast ($m), 2010-2022

Table 5.10 Opalmon Sales Forecast ($m), 2010-2022

Table 5.11 Angiomax Sales Forecast ($m), 2010-2022

Table 5.12 Activase Sales Forecast ($m), 2010-2022

Table 5.13 Newly Launched Drugs, 2009-2011

Table 5.14 Effient Sales Forecast ($m), 2010-2022

Table 5.15 Pradaxa Sales Forecast ($m), 2011-2022

Table 5.16 Brilinta Sales Forecast ($m), 2011-2022

Table 5.17 Xarelto Sales Forecast ($m), 2011-2022

Table 6.1 Platelet Aggregation Inhibitors: R&D Pipeline, 2011

Table 6.2 Heparin Drugs: R&D Pipeline, 2011

Table 6.3 Fibrinolytics: R&D Pipeline, 2011

Table 6.4 Direct Thrombin Inhibitors: R&D Pipeline, 2011

Table 6.5 Direct Factor Xa Inhibitors: R&D Pipeline, 2011

Table 6.6 R&D Pipeline for Other Antithrombotic Agents, 2011

Table 7.1 SWOT Analysis, 2012-2022

Table 7.2 STEP Analysis, 2012-2022

Table 9.1 World Market Forecast ($bn), 2010-2022

 

List of Figures

 

Figure 3.1 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022

Figure 3.2 Leading Antithrombotic/Anticoagulant Therapeutic Classes: Market Shares (%), 2010

Figure 3.3 Leading Therapeutic Class Forecast: Market Shares (%), 2012

Figure 3.4 Leading Therapeutic Class Forecast: Market Shares (%), 2022

Figure 3.5 Platelet Aggregation Inhibitors: Market Forecast ($bn), 2010-2022

Figure 3.6 Heparins: Market Forecast ($bn), 2010-2022

Figure 3.7 Fibrinolytics: Market Forecast ($bn), 2010-2022

Figure 3.8 Vitamin K Antagonists: Market Forecast ($bn), 2010-2022

Figure 3.9 Direct Thrombin Inhibitors: Market Forecast ($bn), 2010-2022

Figure 3.10 Direct Factor Xa Inhibitors: Market Forecast ($bn), 2010-2022

Figure 3.11 Antithrombotic/Anticoagulant Drugs: Therapeutic Class Market Shares (%), 2010, 2012 & 2022

Figure 4.1 Antithrombotic/Anticoagulant Drugs: Market Shares (%) by Country, 2010

Figure 4.2 Antithrombotic/Anticoagulant Drugs: Market Shares (%) by Country, 2012

Figure 4.3 Antithrombotic/Anticoagulant Drugs: Market Shares (%) by Country, 2022

Figure 4.4 US Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022

Figure 4.5 Japanese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022

Figure 4.6 Leading European Antithrombotic/Anticoagulant Drug Market Forecasts ($bn), 2010-2022

Figure 4.7 Chinese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022

Figure 4.8 Indian Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022

Figure 5.1 Leading Antithrombotic/Anticoagulant Drugs: Sales ($m) and Market Shares (%), 2010

Figure 5.2 Plavix Sales Forecast ($m), 2010-2022

Figure 5.3 Lovenox Sales Forecast ($m), 2010-2022

Figure 5.4 Pletal Sales Forecast ($m), 2010-2022

Figure 5.5 Fragmin Sales Forecast ($m), 2010-2022

Figure 5.6 Asasantin Sales Forecast ($m), 2010-2022

Figure 5.7 Arixtra Sales Forecast ($m), 2010-2022

Figure 5.8 Aspirin Cardio Sales Forecast ($m), 2010-2022

Figure 5.9 Opalmon Sales Forecast ($m), 2010-2022

Figure 5.10 Angiomax Sales Forecast ($m), 2010-2022

Figure 5.11 Activase Sales Forecast ($m), 2010-2022

Figure 5.12 Effient Sales Forecast ($m), 2010-2022

Figure 5.13 Pradaxa Sales Forecast ($m), 2011-2022

Figure 5.14 Brilinta Sales Forecast ($m), 2011-2022

Figure 5.15 Xarelto Sales Forecast ($m), 2011-2022

Figure 6.1 New Antithrombotic Agents

Figure 9.1 Leading Drug Classes: Sales Forecasts ($bn), 2010-2022

Figure 9.2 Leading Drugs: Sales Projections ($m), 2010, 2012 & 2022

Figure 9.3 Leading National Markets: Sales Projections ($bn), 2010, 2012 & 2022

 

Companies Listed

 

Abbott

Ablynx

Acino Pharma

ARCA Discovery

Archemix

Arena Pharmaceuticals

Artisan Pharma

Asahi Kasei Pharma

AstraZeneca

ARYx Therapeutics

Barr Pharmaceuticals

Bayer Healthcare

Berlex

Bharat Biotech

BioInvent

BioVascular

Boehringer Ingelheim

Bristol-Myers Squibb (BMS)

Canyon Pharmaceuticals

Cardiome Pharma

Center for Medicaid and Medicare Services

Daiichi Sankyo

Dainippon Sumitomo

Dr. Reddy's Laboratories

Eisai Pharmaceuticals

Eli Lilly

Endotis Pharma

European Medicines Agency (EMA)

Food and Drug Administration (US FDA)

Genentech

GlaxoSmithKline (GSK)

Janssen

Johnson & Johnson (J&J)

Kowa

Kyowa Hakko

LIMES Institute

Lundbeck

McMaster University

Merck & Co.

Mitsubishi Kasei

Momenta

Myriad Genetics

New Mexico Heart Institute

Novartis

Ono Pharmaceutical

Organon

Otsuka Pharmaceuticals

PAION

Pfizer

Pharmacia

Pharmacyclics

Polymedix

Portola Pharmaceuticals

POZEN

Ranbaxy

Regado Biosciences

Roche

Rovi Pharmaceuticals

Sandoz (part of Novartis)

Sanofi

Speedel

Takeda Pharmaceutical

Talecris Biotherapeutics

Teva Pharmaceuticals

The Medicines Company

The Mount Sinai Medical Center

Trigen Pharma

ThromboGenics

Thrombosis & Atherosclerosis Research Institute, Ontario

Virginia Commonwealth University

Watson Pharmaceuticals

Western Therapeutics Institute

World Health Organization (WHO)

Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai Medical Center

 

 

 

To order this report:

Drug and Medication Industry: Antithrombotic/Anticoagulant Drugs: World Market 2012-2022

 

 

More Market Research Report

 

 

 

Check our Industry Analysis and Insights

 

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Ophthalmic Drugs: World Market Prospects 2012-2022
2. Antibody Drugs: Technologies and Global Markets
3. Antibacterial Drugs: World Market Prospects 2012-2022
4. Generic Drugs: World Market Outlook 2011-2021
5. Multi-therapy Drugs: Opportunities for Generics & Biosimilars
6. Generic Drugs: The Global Market--Focus on Europe
7. Generic Drugs: The Global Market--Focus on Asia
8. Generic Drugs: The Global Market
9. Generic Drugs: The Global Market: Focus on the Americas
10. Reportlinker Adds Leading Anti-Cancer Drugs: World Market Prospects 2011-2021
11. FDA CONSUMER HEALTH INFORMATION - Combating Misuse and Abuse of Prescription Drugs: Q&A with Michael Klein, Ph.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016 ALSP, Inc. announced ... MD as Consultant for Medical Affairs in preparation for its ... Michael Pierschbacher , PhD, CEO, stated, "We are pleased to ... look forward to working with an individual of such practical ... look forward to drawing deeply on his broad experience and ...
(Date:2/10/2016)... KANSAS CITY, Mo. , Feb. 10, 2016 ... the pharmaceutical industry, recently identified an industry-wide trend ... a tool that allows organizations to efficiently deliver ... surveys, one in 2011 and another in 2015, ... are armed with tablet devices and DSAs, many ...
(Date:2/10/2016)... HALLANDALE, Fla. , Feb. 9, 2016  Until ... sagging were surgery or liposuction. Thankfully, the FDA approved ... freezing them to death. Coolsculpting was originally approved in ... to the thighs and now the chin. With this ... Wellness Center can use a smaller applicator, the CoolMini, ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined the ... available to physicians. The integration will enable Allscripts users to post open appointments ... free mobile app. , The partnership gives Everseat substantial added power to help ...
(Date:2/10/2016)... Jacksonville, Florida (PRWEB) , ... ... ... of North Florida – 1 UNF Drive, Jacksonville, FL 32224, February 26th: ... $30, February 27th: Elite Division - Time: 7:00pm – 10:00pm | Ticket ...
(Date:2/10/2016)... ... 2016 , ... Workrite Ergonomics, who is celebrating their 25th year of business ... being an internationally recognized leader in their industry. , "We are very proud of ... of Workrite. “Workrite recognized the importance of good ergonomics before most of our ...
(Date:2/10/2016)... ... , ... Anxiety of older Americans over steep cost increases of prescription drugs ... ago, according to The Senior Citizens League (TSCL). Since last fall, ... rapidly rising costs. “The implications are chilling, particularly for people with chronic health ...
(Date:2/10/2016)... Puente, California (PRWEB) , ... February 09, 2016 ... ... Medicine students, faculty and staff helped give free oral screenings to 150 children ... Feb. 5, 2016. , The College of Dental Medicine joined Chinese American Dental ...
Breaking Medicine News(10 mins):